Xintian Pharma(SZ:002873) Zheng Quan Shi Bao Wang·2025-10-21 07:05Core Viewpoint - New Tian Pharmaceutical has received approval for clinical trials of its Xinlikang capsules, which are aimed at treating cancer-related fatigue in colorectal cancer patients, potentially accelerating the development of its innovative drug pipeline and creating new growth opportunities for the company [2][4]. Group 1: Clinical Trial Approval - The Xinlikang capsules (CXZL2500054) have been approved for clinical trials to treat cancer-related fatigue, enhancing their therapeutic indications for colorectal cancer patients [2][4]. - The approval is expected to expedite the research and development process for the company's innovative drug pipeline, which may lead to new revenue streams [2][5]. Group 2: Market Demand and Potential - Cancer-related fatigue (CRF) is a significant clinical symptom affecting cancer patients, with incidence rates reaching 40% during diagnosis, 62%-85% during treatment, and 30% during follow-up [3]. - The market for CRF treatment in China is projected to reach 18 billion yuan by 2025, indicating a substantial unmet clinical need [5]. - If Xinlikang successfully gains approval for treating CRF in colorectal cancer patients, it has the potential to become a billion-yuan product due to the high prevalence of colorectal cancer [6]. Group 3: R&D Investment and Pipeline - New Tian Pharmaceutical has significantly increased its R&D investment over the past five years, positioning itself as a leader in traditional Chinese medicine innovation [6]. - The company currently has over 10 proprietary products in its pipeline, including several innovative traditional Chinese medicines in various stages of clinical trials [6][7]. - In 2024, New Tian Pharmaceutical's R&D expenses are projected to be 40 million yuan, with a research expense ratio of 4.7%, ranking it among the top in its category [6].